Company news

Share this article:
Mylan Pharmaceuticals has entered into a deal with Novartis to market letrozole 2.5 mg tablets, a generic version of Novartis's breast cancer product Femara. Letrozole tablets posted U.S. sales of approximately $470 million for the 12 month period ending Sept. 30, 2008, according to a Mylan statement. 
 
Titan Pharmaceuticals, a manufacturer focused primarily on the development and commercialization of Probuphine, a treatment for opiate addiction, has reduced its workforce by 40%. Further staff reductions are anticipated in the next several weeks, a company statement said. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.